Janssen has announced new data from the DISCOVER-1 and DISCOVER-2 Phase III trials, evaluating Tremfya (guselkumab) in active psoriatic arthritis (PsA).

The 24-week data showed at least a 20% improvement in disease signs and symptoms compared to placebo.

Further, 75% of patients receiving a dose every four weeks and 57% receiving a dose every eight weeks achieved an IGA score of 0 (Cleared) or 1 (Minimal) and a >2 grade reduction, compared to 15% of those receiving placebo.

The company also announced that in the trials, observed adverse events (AEs) were generally consistent with previous studies of Tremfya and current prescribing information.

“People living with psoriatic arthritis cope with symptoms like pain, joint swelling, and irreversible joint damage that may interfere with their daily activities,” reminded Atul Deodhar, professor of Medicine, Oregon Health & Science University and study steering committee member.

“These data show guselkumab as a potential treatment option to help patients living with this serious disease.”

The drug, a human monoclonal antibody, already holds marketing authorisation in the European Union and is approved in the US, Canada, Japan and several other countries worldwide for the treatment of adult patients with moderate to severe plaque psoriasis.

Psoriatic arthritis is a chronic, immune-mediated inflammatory disease characterised by both joint inflammation and the skin lesions associated with psoriasis. Up to a third of the 14 million people who are living with psoriasis in Europe will also develop PsA.